Naranjo-Rojas Anisbed, Perula-de Torres Luis Ángel, Cruz-Mosquera Freiser Eccehomo, Molina-Recio Guillermo
Health and Education Research Group (GINEYSA), Faculty of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.
Biomedicine Doctoral Program, University of Córdoba, Córdoba, Spain.
J Med Internet Res. 2025 Jan 6;27:e65888. doi: 10.2196/65888.
Chronic obstructive pulmonary disease (COPD) primarily originates from exposure to tobacco smoke, although factors, such as air pollution and exposure to chemicals, also play a role. One of the primary treatments for COPD is oxygen therapy, which helps manage dyspnea and improve survival rates. Mobile health (mHealth) technologies have demonstrated significant potential in monitoring patients with chronic diseases, offering new avenues for enhancing patient care and disease management.
The purpose of this study was to evaluate the efficacy and acceptability of a mobile app designed for the clinical monitoring of patients with COPD and home oxygen (HO) therapy, compared with conventional monitoring in real-world community settings.
A parallel-group, nonblinded, multicenter randomized controlled trial was conducted with 45 participants; the intervention group (IG), which used the mobile app in addition to conventional monitoring (n=23) and the control group, which received only conventional monitoring (n=22), administered by therapists over a duration of 3 months. The primary outcomes included the chronic obstructive pulmonary disease assessment test (CAT) score, the level of dyspnea measured by the Borg scale, and oxygen saturation percentage, assessed at both the beginning and end of the trial. Secondary outcomes included the frequency of app use, the number of hospitalizations, and survival rates. In addition, a satisfaction survey and an interview were conducted with the IG.
The median use of the mobile app was 21 (IQR 16-28) days. At the end of the follow-up, the Borg dyspnea scale was significantly lower in patients who used the mobile app for HO therapy monitoring (mean 0.6, SD 0.8 vs mean 4.1, SD 1.4; P=.001). Regarding the impact of COPD on quality of life, as measured by the CAT, no differences were found in the scores between baseline and end-of-follow-up within the control group. However, a significant decrease was observed in the IG (baseline median CAT 27, IQR 23-31 vs final median CAT 22, IQR 14-28; P<.001). In addition, the CAT score was significantly higher in patients receiving conventional monitoring compared with those monitored with the mobile app (median 30, IQR 23-32 vs median 22, IQR 14-28; P=.02).
The use of the mobile app, AppO2 (SINCO), designed for the clinical monitoring of patients with COPD and HO therapy, is associated with improved quality of life. In addition, the app is highly accepted by users, promotes self-care, and fosters patient confidence in managing their own condition.
ClinicalTrials NCT04820790; https://clinicaltrials.gov/study/NCT04820790.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-https://doi.org/10.1186/s12875-021-01450-8.
慢性阻塞性肺疾病（COPD）主要源于接触烟草烟雾，尽管空气污染和接触化学物质等因素也起作用。COPD的主要治疗方法之一是氧疗，其有助于控制呼吸困难并提高生存率。移动健康（mHealth）技术在监测慢性病患者方面已显示出巨大潜力，为加强患者护理和疾病管理提供了新途径。
本研究旨在评估一款专为COPD患者临床监测和家庭氧疗（HO）设计的移动应用程序与现实社区环境中的传统监测相比的疗效和可接受性。
进行了一项平行组、非盲、多中心随机对照试验，有45名参与者；干预组（IG）除接受传统监测外还使用移动应用程序（n = 23），对照组仅接受传统监测（n = 22），由治疗师在3个月的时间内进行管理。主要结局包括慢性阻塞性肺疾病评估测试（CAT）评分、用Borg量表测量的呼吸困难程度以及氧饱和度百分比，在试验开始和结束时进行评估。次要结局包括应用程序的使用频率、住院次数和生存率。此外，对IG进行了满意度调查和访谈。
移动应用程序的中位使用天数为21天（四分位间距16 - 28天）。在随访结束时，使用移动应用程序进行HO治疗监测的患者的Borg呼吸困难量表得分显著更低（平均值0.6，标准差0.8对比平均值4.1，标准差1.4；P = 0.001）。关于COPD对生活质量的影响，用CAT衡量，对照组在基线和随访结束时的得分没有差异。然而，IG组观察到显著下降（基线CAT中位数27，四分位间距23 - 31对比最终CAT中位数22，四分位间距14 - 28；P < 0.001）。此外，接受传统监测的患者的CAT评分显著高于使用移动应用程序监测的患者（中位数30，四分位间距23 - 32对比中位数22，四分位间距14 - 28；P = 0.02）。
使用专为COPD患者临床监测和HO治疗设计的移动应用程序AppO2（SINCO）与生活质量改善相关。此外，该应用程序受到用户高度接受，促进自我护理，并增强患者对管理自身病情的信心。
ClinicalTrials NCT04820790；https://clinicaltrials.gov/study/NCT04820790。
国际注册报告标识符（IRRID）：RR2 - https://doi.org/10.1186/s12875 - 021 - 01450 - 8。
